Prudential PLC boosted its stake in PerkinElmer, Inc. (NYSE:PKI – Get Rating) by 105.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,398 shares of the medical research company’s stock after purchasing an additional 3,286 shares during the quarter. Prudential PLC’s holdings in PerkinElmer were worth $897,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of PKI. Covestor Ltd grew its position in PerkinElmer by 25.1% in the 1st quarter. Covestor Ltd now owns 359 shares of the medical research company’s stock valued at $63,000 after buying an additional 72 shares in the last quarter. Texas Permanent School Fund lifted its holdings in PerkinElmer by 0.4% in the 4th quarter. Texas Permanent School Fund now owns 17,934 shares of the medical research company’s stock valued at $2,515,000 after acquiring an additional 74 shares during the last quarter. D.A. Davidson & CO. lifted its holdings in PerkinElmer by 5.3% in the 1st quarter. D.A. Davidson & CO. now owns 1,582 shares of the medical research company’s stock valued at $276,000 after acquiring an additional 80 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in PerkinElmer by 1.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 7,334 shares of the medical research company’s stock valued at $1,043,000 after acquiring an additional 80 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC lifted its holdings in PerkinElmer by 1.7% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 5,282 shares of the medical research company’s stock valued at $741,000 after acquiring an additional 87 shares during the last quarter. 85.22% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, insider Andrew Okun sold 2,435 shares of the stock in a transaction that occurred on Thursday, April 13th. The stock was sold at an average price of $136.51, for a total transaction of $332,401.85. Following the completion of the sale, the insider now directly owns 4,356 shares of the company’s stock, valued at approximately $594,637.56. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, insider Maxwell Krakowiak sold 322 shares of the stock in a transaction that occurred on Wednesday, March 29th. The stock was sold at an average price of $130.00, for a total value of $41,860.00. Following the completion of the sale, the insider now owns 7,202 shares of the company’s stock, valued at approximately $936,260. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Andrew Okun sold 2,435 shares of the stock in a transaction that occurred on Thursday, April 13th. The shares were sold at an average price of $136.51, for a total value of $332,401.85. Following the completion of the sale, the insider now directly owns 4,356 shares of the company’s stock, valued at approximately $594,637.56. The disclosure for this sale can be found here. In the last three months, insiders sold 15,349 shares of company stock valued at $1,953,042. 0.52% of the stock is owned by corporate insiders.
PerkinElmer Stock Down 0.9 %
PerkinElmer (NYSE:PKI – Get Rating) last issued its quarterly earnings results on Thursday, May 11th. The medical research company reported $1.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.06). The company had revenue of $674.87 million for the quarter, compared to analyst estimates of $686.30 million. PerkinElmer had a return on equity of 13.94% and a net margin of 14.69%. During the same quarter last year, the company earned $2.41 EPS. As a group, equities research analysts expect that PerkinElmer, Inc. will post 5.06 earnings per share for the current fiscal year.
PerkinElmer Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, August 11th. Investors of record on Friday, July 21st will be paid a dividend of $0.07 per share. The ex-dividend date is Thursday, July 20th. This represents a $0.28 dividend on an annualized basis and a yield of 0.24%. PerkinElmer’s payout ratio is 3.65%.
Wall Street Analyst Weigh In
PKI has been the subject of a number of research analyst reports. StockNews.com initiated coverage on shares of PerkinElmer in a report on Thursday, March 16th. They issued a “hold” rating for the company. Robert W. Baird dropped their price objective on PerkinElmer from $182.00 to $165.00 in a report on Friday, May 12th. Stifel Nicolaus dropped their price objective on PerkinElmer from $145.00 to $135.00 in a report on Friday, May 12th. Citigroup lowered their price target on PerkinElmer from $170.00 to $160.00 in a report on Monday. Finally, Credit Suisse Group reiterated a “neutral” rating and set a $160.00 price target on shares of PerkinElmer in a report on Wednesday, February 15th. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $158.60.
About PerkinElmer
PerkinElmer, Inc engages in the provision of products, services, and solutions for diagnostics, food, environmental, life sciences, and applied markets. It operates through the following segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment consists of technologies that help life sciences researchers better understand diseases and develop treatments.
Read More
- Get a free copy of the StockNews.com research report on PerkinElmer (PKI)
- How to Calculate Stock Growth
- 7 Best Retail Stocks to Invest in
- 3 Home Improvement Stocks to Renovate Your Portfolio
- Beam Global Shines Brightly in the EV Infrastructure Space
- Canoo Bottoms As Production Ramp Gets CloserÂ
Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI – Get Rating).
Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.
